Figure 1.

For most targeted therapies, drug sensitivity varies as a function of both cancer type and the specific mutant allele present. Future matching algorithms should give varying weight to alterations based on these factors, with compelling clinical evidence in the patient’s specific disease type and mutant allele conferring the greatest weight. A primarly limitation of current cancer precision paradigms is that few alterations identified by clinical tumor profiling are predictive of drug response based on compelling clinical data generated in the context of the patient’s specific mutant allele and disease type.